View Future GrowthBio-Gate 過去の業績過去 基準チェック /06Bio-Gateの収益は年間平均-20%の割合で減少していますが、 Chemicals業界の収益は年間 減少しています。収益は年間4.4% 7.9%割合で 増加しています。主要情報-20.04%収益成長率-14.20%EPS成長率Chemicals 業界の成長12.41%収益成長率7.93%株主資本利益率-156.60%ネット・マージン-19.71%前回の決算情報30 Jun 2025最近の業績更新Reported Earnings • Aug 03Full year 2024 earnings releasedFull year 2024 results: Revenue: €7.21m (down 1.3% from FY 2023). Net loss: €1.62m (flat on FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.すべての更新を表示Recent updatesNew Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (€5.81m market cap, or US$6.83m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).New Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€809k free cash flow). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (€7.74m market cap, or US$9.14m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).お知らせ • Aug 07Bio-Gate AG, Annual General Meeting, Sep 12, 2025Bio-Gate AG, Annual General Meeting, Sep 12, 2025, at 10:00 W. Europe Standard Time.New Risk • Aug 03New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.3m free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (€8.74m market cap, or US$10.1m).Reported Earnings • Aug 03Full year 2024 earnings releasedFull year 2024 results: Revenue: €7.21m (down 1.3% from FY 2023). Net loss: €1.62m (flat on FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.New Risk • Jul 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.37m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€8.37m market cap, or US$9.88m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • Mar 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.2m free cash flow). Earnings have declined by 18% per year over the past 5 years. Market cap is less than US$10m (€6.52m market cap, or US$7.05m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.9% average weekly change).New Risk • Sep 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€1.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.2m free cash flow). Earnings have declined by 18% per year over the past 5 years. Market cap is less than US$10m (€8.22m market cap, or US$9.06m). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).収支内訳Bio-Gate の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史XTRA:BIG1 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費30 Jun 257-13031 Mar 257-13031 Dec 247-23030 Sep 247-23030 Jun 248-23031 Mar 247-23031 Dec 237-23030 Sep 237-23030 Jun 237-13031 Mar 236-23031 Dec 226-23030 Sep 226-23030 Jun 226-23031 Mar 226-13031 Dec 216-12030 Sep 216-12030 Jun 216-12031 Mar 216-12031 Dec 205-12030 Sep 205-12030 Jun 205-12031 Mar 204-12031 Dec 194-12030 Sep 193-12030 Jun 193-12031 Mar 194-12031 Dec 184-12030 Sep 184-12030 Jun 18502031 Mar 18402031 Dec 17402030 Sep 17402030 Jun 17402031 Mar 17402031 Dec 16401030 Sep 16401030 Jun 16401031 Mar 16301031 Dec 153-11030 Sep 153-11030 Jun 153-110質の高い収益: BIG1は現在利益が出ていません。利益率の向上: BIG1は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: BIG1は利益が出ておらず、過去 5 年間で損失は年間20%の割合で増加しています。成長の加速: BIG1の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: BIG1は利益が出ていないため、過去 1 年間の収益成長をChemicals業界 ( -13.5% ) と比較することは困難です。株主資本利益率高いROE: BIG1は現在利益が出ていないため、自己資本利益率 ( -156.6% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/08 13:50終値2026/05/08 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bio-Gate AG 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Cosmin FilkerGBC AGMatthias GreiffenbergerGBC AG
Reported Earnings • Aug 03Full year 2024 earnings releasedFull year 2024 results: Revenue: €7.21m (down 1.3% from FY 2023). Net loss: €1.62m (flat on FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.
New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (€5.81m market cap, or US$6.83m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
New Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€809k free cash flow). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (€7.74m market cap, or US$9.14m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
お知らせ • Aug 07Bio-Gate AG, Annual General Meeting, Sep 12, 2025Bio-Gate AG, Annual General Meeting, Sep 12, 2025, at 10:00 W. Europe Standard Time.
New Risk • Aug 03New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.3m free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (€8.74m market cap, or US$10.1m).
Reported Earnings • Aug 03Full year 2024 earnings releasedFull year 2024 results: Revenue: €7.21m (down 1.3% from FY 2023). Net loss: €1.62m (flat on FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.
New Risk • Jul 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.37m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€8.37m market cap, or US$9.88m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • Mar 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.2m free cash flow). Earnings have declined by 18% per year over the past 5 years. Market cap is less than US$10m (€6.52m market cap, or US$7.05m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.9% average weekly change).
New Risk • Sep 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€1.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.2m free cash flow). Earnings have declined by 18% per year over the past 5 years. Market cap is less than US$10m (€8.22m market cap, or US$9.06m). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).